Limits...
Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF.

Yano H, Ishida T, Imada K, Sakai T, Ishii T, Inagaki A, Iida S, Uchiyama T, Ueda R - Br. J. Haematol. (2008)

View Article: PubMed Central - PubMed

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Because tumour cells from most ATLL patients express CCR4, we postulated that this molecule might represent a novel molecular target for immunotherapy and developed a chimeric anti-CCR4 monoclonal antibody (mAb), KM2760... Antibody-dependent cellular cytotoxicity (ADCC) is one of the most important mechanisms of action of therapeutic mAb... Although ADCC depends on the cytotoxic activity of effector cells, such as natural killer (NK) cells, monocytes/macrophages and neutrophils, these cells are commonly qualitatively suppressed and quantitatively reduced in cancer patients... To overcome this problem, the Fc region of KM2760 is defucosylated, which results in enhanced ADCC... The significance of differences in the tumour volume among the groups was estimated by the Mann–Whitney U-test... In this study, P < 0·05 was considered significant... However, KM2760 (10 μg/ml) failed to induce any ADCC against S-YU cells in the presence of granulocytes from either G-CSF-injected or naïve SCID mice at any E/T ratio (data not shown)... Monocytes/macrophages were prepared from peritoneal exudate cells of 14 SCID mice receiving 10 μg G-CSF twice (at 20 h and 5 h before testing) or 15 naïve SCID mice... As S-YU does not express CD20, rituximab (Chugai Pharmaceutical Co., Ltd, Tokyo, Japan) was used as a control mAb for KM2760... PKH26 (Sigma-Aldrich, St Louis, MO, USA) labelled S-YU (1 × 10) and pooled monocytes/macrophages from 14 G-CSF-injected or 15 naïve SCID mice (5 × 10) were co-cultured with or without KM2760 or rituximab at a final concentration of 10 μg/ml for 1 h... The percentage of spontaneous, rituximab-induced, and KM2760-induced phagocytosis of S-YU mediated by pooled monocytes/macrophages from 15 naïve SCID mice was 8·6%, 13·4% and 21·5% respectively, whereas these values from 14 G-CSF primed SCID mice were 19·2%, 17·8% and 30·6% respectively (Fig 2A and B)... These findings indicate that human G-CSF augments not only natural phagocytosis but also KM2760-induced phagocytosis of S-YU by mouse monocytes/macrophages, although the underlying mechanisms require further clarification... The data presented here are the first to address the potential G-CSF-induced augmentation of monocytes/macrophages in the antitumour activity of a therapeutic mAb in an in vivo animal model... In conclusion, the present study is the first to report that antitumour activity induced by next-generation defucosylated therapeutic mAb was strongly augmented by the immunomodulatory agent G-CSF in vivo.

Show MeSH

Related in: MedlinePlus

KM2760-induced potent antitumour activity in the Adult T-cell leukaemia/lymphoma (ATLL) tumour-bearing mouse model in the therapeutic setting (A) Total white blood cell, granulocyte and monocyte counts in blood of mice injected with 1, 3 or 10 μg granulocyte colony-stimulating factor (G-CSF) on days 1–7 were measured. Each group consists of three mice, and the blood cell counts are presented as mean + SD (x109 cells/l). Arrows, G-CSF injection; •, total white blood cells; □, granulocytes; and Δ, monocytes. (B) Antitumour activity of KM2760 against pre-established subcutaneous S-YU tumours. Tumour volume was calculated by the following formula: Tumour volume (mm3) = 0·5 × (major diameter) × (minor diameter)2. Injections of KM2760 or saline were started when tumours were about 609 mm3 (12 d after S-YU inoculation). The tumour volume is presented as mean (mm3). Arrowheads indicate KM2760 or control injections and arrows indicate G-CSF or control injections. Each group consists of five mice. •, control (saline); ○, KM2760; ▪, G-CSF; and □, KM2760 plus G-CSF. A significant differences between the groups are indicated by #P < 0·01 or *P < 0·05. (C) The photographs of each mouse were taken at day 27 from the start of treatment.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2268953&req=5

fig01: KM2760-induced potent antitumour activity in the Adult T-cell leukaemia/lymphoma (ATLL) tumour-bearing mouse model in the therapeutic setting (A) Total white blood cell, granulocyte and monocyte counts in blood of mice injected with 1, 3 or 10 μg granulocyte colony-stimulating factor (G-CSF) on days 1–7 were measured. Each group consists of three mice, and the blood cell counts are presented as mean + SD (x109 cells/l). Arrows, G-CSF injection; •, total white blood cells; □, granulocytes; and Δ, monocytes. (B) Antitumour activity of KM2760 against pre-established subcutaneous S-YU tumours. Tumour volume was calculated by the following formula: Tumour volume (mm3) = 0·5 × (major diameter) × (minor diameter)2. Injections of KM2760 or saline were started when tumours were about 609 mm3 (12 d after S-YU inoculation). The tumour volume is presented as mean (mm3). Arrowheads indicate KM2760 or control injections and arrows indicate G-CSF or control injections. Each group consists of five mice. •, control (saline); ○, KM2760; ▪, G-CSF; and □, KM2760 plus G-CSF. A significant differences between the groups are indicated by #P < 0·01 or *P < 0·05. (C) The photographs of each mouse were taken at day 27 from the start of treatment.

Mentions: Human G-CSF increased granulocyte counts in a dose-dependent manner in severe-combined immunodeficient (SCID) mice (Fig 1A). Subsequently, we evaluated KM2760-induced antitumour activity in the ATLL tumour-bearing mouse model with or without G-CSF in the disseminated setting. The ATLL cell line S-YU (Imada et al, 1996) was positive for CCR4 by flow cytometric analysis (data not shown). 1·5 × 107 S-YU cells were inoculated s.c. into SCID mice. The tumour-bearing mice were divided into four groups of five each for treatment with KM2760 or control (saline), KM2760 plus G-CSF or G-CSF alone, to ensure that the mean tumour volumes were same in each group. KM2760 (20 mg/kg) or saline injections into the tail veins of the mice were started 12 d after tumour inoculation, and continued weekly for 4 weeks. The significance of differences in the tumour volume among the groups was estimated by the Mann–Whitney U-test. In this study, P < 0·05 was considered significant. G-CSF (10 μg/mouse) was injected s.c. into SCID mice on days 0–6 and 14–20 from the start of KM2760 treatment. Mean tumour volumes in KM2760 recipients and control mice 27 d after the start of KM2760 treatment were 1174 ± 409 and 5015 ± 1033 mm3 respectively (P = 0·0090). KM2760 combined with G-CSF treatment yielded an even more robust antitumour effect, with all recipients achieving complete remission, i.e. subcutaneous S-YU tumours completely vanished. The difference between the tumour volume in animals treated with KM2760 plus G-CSF and those with KM2760 alone was highly significant (P = 0·0053) (Fig 1B and C). None of the mice in the present study showed evidence of toxicity that could be attributed to the KM2760 and/or the G-CSF injections. These findings indicate that human G-CSF significantly augments the antitumour activity of KM2760 in the ATLL tumour-bearing mouse model.


Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF.

Yano H, Ishida T, Imada K, Sakai T, Ishii T, Inagaki A, Iida S, Uchiyama T, Ueda R - Br. J. Haematol. (2008)

KM2760-induced potent antitumour activity in the Adult T-cell leukaemia/lymphoma (ATLL) tumour-bearing mouse model in the therapeutic setting (A) Total white blood cell, granulocyte and monocyte counts in blood of mice injected with 1, 3 or 10 μg granulocyte colony-stimulating factor (G-CSF) on days 1–7 were measured. Each group consists of three mice, and the blood cell counts are presented as mean + SD (x109 cells/l). Arrows, G-CSF injection; •, total white blood cells; □, granulocytes; and Δ, monocytes. (B) Antitumour activity of KM2760 against pre-established subcutaneous S-YU tumours. Tumour volume was calculated by the following formula: Tumour volume (mm3) = 0·5 × (major diameter) × (minor diameter)2. Injections of KM2760 or saline were started when tumours were about 609 mm3 (12 d after S-YU inoculation). The tumour volume is presented as mean (mm3). Arrowheads indicate KM2760 or control injections and arrows indicate G-CSF or control injections. Each group consists of five mice. •, control (saline); ○, KM2760; ▪, G-CSF; and □, KM2760 plus G-CSF. A significant differences between the groups are indicated by #P < 0·01 or *P < 0·05. (C) The photographs of each mouse were taken at day 27 from the start of treatment.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2268953&req=5

fig01: KM2760-induced potent antitumour activity in the Adult T-cell leukaemia/lymphoma (ATLL) tumour-bearing mouse model in the therapeutic setting (A) Total white blood cell, granulocyte and monocyte counts in blood of mice injected with 1, 3 or 10 μg granulocyte colony-stimulating factor (G-CSF) on days 1–7 were measured. Each group consists of three mice, and the blood cell counts are presented as mean + SD (x109 cells/l). Arrows, G-CSF injection; •, total white blood cells; □, granulocytes; and Δ, monocytes. (B) Antitumour activity of KM2760 against pre-established subcutaneous S-YU tumours. Tumour volume was calculated by the following formula: Tumour volume (mm3) = 0·5 × (major diameter) × (minor diameter)2. Injections of KM2760 or saline were started when tumours were about 609 mm3 (12 d after S-YU inoculation). The tumour volume is presented as mean (mm3). Arrowheads indicate KM2760 or control injections and arrows indicate G-CSF or control injections. Each group consists of five mice. •, control (saline); ○, KM2760; ▪, G-CSF; and □, KM2760 plus G-CSF. A significant differences between the groups are indicated by #P < 0·01 or *P < 0·05. (C) The photographs of each mouse were taken at day 27 from the start of treatment.
Mentions: Human G-CSF increased granulocyte counts in a dose-dependent manner in severe-combined immunodeficient (SCID) mice (Fig 1A). Subsequently, we evaluated KM2760-induced antitumour activity in the ATLL tumour-bearing mouse model with or without G-CSF in the disseminated setting. The ATLL cell line S-YU (Imada et al, 1996) was positive for CCR4 by flow cytometric analysis (data not shown). 1·5 × 107 S-YU cells were inoculated s.c. into SCID mice. The tumour-bearing mice were divided into four groups of five each for treatment with KM2760 or control (saline), KM2760 plus G-CSF or G-CSF alone, to ensure that the mean tumour volumes were same in each group. KM2760 (20 mg/kg) or saline injections into the tail veins of the mice were started 12 d after tumour inoculation, and continued weekly for 4 weeks. The significance of differences in the tumour volume among the groups was estimated by the Mann–Whitney U-test. In this study, P < 0·05 was considered significant. G-CSF (10 μg/mouse) was injected s.c. into SCID mice on days 0–6 and 14–20 from the start of KM2760 treatment. Mean tumour volumes in KM2760 recipients and control mice 27 d after the start of KM2760 treatment were 1174 ± 409 and 5015 ± 1033 mm3 respectively (P = 0·0090). KM2760 combined with G-CSF treatment yielded an even more robust antitumour effect, with all recipients achieving complete remission, i.e. subcutaneous S-YU tumours completely vanished. The difference between the tumour volume in animals treated with KM2760 plus G-CSF and those with KM2760 alone was highly significant (P = 0·0053) (Fig 1B and C). None of the mice in the present study showed evidence of toxicity that could be attributed to the KM2760 and/or the G-CSF injections. These findings indicate that human G-CSF significantly augments the antitumour activity of KM2760 in the ATLL tumour-bearing mouse model.

View Article: PubMed Central - PubMed

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Because tumour cells from most ATLL patients express CCR4, we postulated that this molecule might represent a novel molecular target for immunotherapy and developed a chimeric anti-CCR4 monoclonal antibody (mAb), KM2760... Antibody-dependent cellular cytotoxicity (ADCC) is one of the most important mechanisms of action of therapeutic mAb... Although ADCC depends on the cytotoxic activity of effector cells, such as natural killer (NK) cells, monocytes/macrophages and neutrophils, these cells are commonly qualitatively suppressed and quantitatively reduced in cancer patients... To overcome this problem, the Fc region of KM2760 is defucosylated, which results in enhanced ADCC... The significance of differences in the tumour volume among the groups was estimated by the Mann–Whitney U-test... In this study, P < 0·05 was considered significant... However, KM2760 (10 μg/ml) failed to induce any ADCC against S-YU cells in the presence of granulocytes from either G-CSF-injected or naïve SCID mice at any E/T ratio (data not shown)... Monocytes/macrophages were prepared from peritoneal exudate cells of 14 SCID mice receiving 10 μg G-CSF twice (at 20 h and 5 h before testing) or 15 naïve SCID mice... As S-YU does not express CD20, rituximab (Chugai Pharmaceutical Co., Ltd, Tokyo, Japan) was used as a control mAb for KM2760... PKH26 (Sigma-Aldrich, St Louis, MO, USA) labelled S-YU (1 × 10) and pooled monocytes/macrophages from 14 G-CSF-injected or 15 naïve SCID mice (5 × 10) were co-cultured with or without KM2760 or rituximab at a final concentration of 10 μg/ml for 1 h... The percentage of spontaneous, rituximab-induced, and KM2760-induced phagocytosis of S-YU mediated by pooled monocytes/macrophages from 15 naïve SCID mice was 8·6%, 13·4% and 21·5% respectively, whereas these values from 14 G-CSF primed SCID mice were 19·2%, 17·8% and 30·6% respectively (Fig 2A and B)... These findings indicate that human G-CSF augments not only natural phagocytosis but also KM2760-induced phagocytosis of S-YU by mouse monocytes/macrophages, although the underlying mechanisms require further clarification... The data presented here are the first to address the potential G-CSF-induced augmentation of monocytes/macrophages in the antitumour activity of a therapeutic mAb in an in vivo animal model... In conclusion, the present study is the first to report that antitumour activity induced by next-generation defucosylated therapeutic mAb was strongly augmented by the immunomodulatory agent G-CSF in vivo.

Show MeSH
Related in: MedlinePlus